Creating genetic resistance to HIV

Current Opinion in Immunology

Volumn 24, Issue 5, 2012, Pages 625-632

  Burnett, John C ^a   Zaia, John A ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LEXGENLEUCEL T; RNA; RRZ1; SB 728 T; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE;

CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL THERAPY; DNA MODIFICATION; DRUG MECHANISM; DRUG POTENCY; GENE EXPRESSION; GENETIC RESISTANCE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; GENETIC THERAPY; HIV-1; HUMANS;

EID: 84867745292     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.08.013     Document Type: Review

References (68)

1. Kiem H.P., Jerome K.R., Deeks S.G., McCune J.M. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 2012, 10:137-147.
2. Deeks S.G., Autran B., Berkhout B., Benkirane M., Cairns S., Chomont N., Chun T.W., Churchill M., Mascio M.D., Katlama C., et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 2:607-614.
3. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003, 9:727-728.
4. Buzon M.J., Massanella M., Llibre J.M., Esteve A., Dahl V., Puertas M.C., Gatell J.M., Domingo P., Paredes R., Sharkey M., et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010, 16:460-465.
5. Yukl S.A., Shergill A.K., McQuaid K., Gianella S., Lampiris H., Hare C.B., Pandori M., Sinclair E., Gunthard H.F., Fischer M., et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010, 24:2451-2460.
6. Baltimore D. Gene therapy. Intracellular immunization. Nature 1988, 335:395-396.
7. Scherer L.J., Rossi J.J. Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet 2011, 20:R100-R107.
8. Kambal A., Mitchell G., Cary W., Gruenloh W., Jung Y., Kalomoiris S., Nacey C., McGee J., Lindsey M., Fury B., et al. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther 2011, 19:584-593.
9. Kamata M., Liu S., Liang M., Nagaoka Y., Chen I.S. Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter. Hum Gene Ther 2010, 21:1555-1567.
10. von Laer D., Hasselmann S., Hasselmann K. Impact of gene-modified T cells on HIV infection dynamics. J. Theor Biol 2006, 238:60-77.
11. Applegate T.L., Birkett D.J., McIntyre G.J., Jaramillo A.B., Symonds G., Murray J.M. In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology 2010, 7:83.
12. Kimpel J., Braun S.E., Qiu G., Wong F.E., Conolle M., Schmitz J.E., Brendel C., Humeau L.M., Dropulic B., Rossi J.J., et al. Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS ONE 2010, 5:e12357.
13. Aviran S., Shah P.S., Schaffer D.V., Arkin A.P. Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol 2010, 6:e1000883.
14. Allers K., Hutter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., Schneider T. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011, 117:2791-2799.
15. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., Schneider T., Hofmann J., Kucherer C., Blau O., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698.
16. Hutter G., Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 2011, 25:273-274.
17. Beard B.C., Trobridge G.D., Ironside C., McCune J.S., Adair J.E., Kiem H.P. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin Invest 2010, 120:2345-2354.
18. Perez E.E., Wang J., Miller J.C., Jouvenot Y., Kim K.A., Liu O., Wang N., Lee G., Bartsevich V.V., Lee Y.L., et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008, 26:808-816.
19. Lombardo A., Genovese P., Beausejour C.M., Colleoni S., Lee Y.L., Kim K.A., Ando D., Urnov F.D., Galli C., Gregory P.D., et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007, 25:1298-1306.
20. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G.M., Kohn D.B., Gregory P.D., Holmes M.C., et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010, 28:839-847.
21. Wilen C.B., Wang J., Tilton J.C., Miller J.C., Kim K.A., Rebar E.J., Sherrill-Mix S.A., Patro S.C., Secreto A.J., Jordan A.P., et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011, 7:e1002020.
22. Yuan J., Wang J., Crain K., Fearns C., Kim K.A., Hua K.L., Gregory P.D., Holmes M.C., Torbett B.E. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther 2012, 20:849-859.
23. Aubert M., Ryu B.Y., Banks L., Rawlings D.J., Scharenberg A.M., Jerome K.R. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS ONE 2011, 6:e16825.
24. Mariyanna L., Priyadarshini P., Hofmann-Sieber H., Krepstakies M., Walz N., Grundhoff A., Buchholz F., Hildt E., Hauber J. Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS ONE 2012, 7:e31576.
25. Sarkar I., Hauber I., Hauber J., Buchholz F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007, 316:1912-1915.
26. Egelhofer M., Brandenburg G., Martinius H., Schult-Dietrich P., Melikyan G., Kunert R., Baum C., Choi I., Alexandrov A., von Laer D. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004, 78:568-575.
27. van Lunzen J., Glaunsinger T., Stahmer I., von Baehr V., Baum C., Schilz A., Kuehlcke K., Naundorf S., Martinius H., Hermann F., et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007, 15:1024-1033.
28. Trobridge G.D., Wu R.A., Beard B.C., Chiu S.Y., Munoz N.M., von Laer D., Rossi J.J., Kiem H.P. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS ONE 2009, 4:e7693.
29. Egerer L., Volk A., Kahle J., Kimpel J., Brauer F., Hermann F.G., von Laer D. Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther 2011, 19:1236-1244.
30. Hermann F.G., Egerer L., Brauer F., Gerum C., Schwalbe H., Dietrich U., von Laer D. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol 2009, 83:4844-4853.
31. Goff S.P. Knockdown screens to knockout HIV-1. Cell 2008, 135:417-420.
32. Vets S., Kimpel J., Volk A., De Rijck J., Schrijvers R., Verbinnen B., Maes W., Von Laer D., Debyser Z., Gijsbers R. Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Mol Ther 2012, 20:908-917.
33. Malim M.H., Bieniasz P.D. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med 2012, 2:a006940.
34. Wang Y., Shao Q., Yu X., Kong W., Hildreth J.E., Liu B. N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination. J Virol 2011, 85:4510-4519.
35. Li L., Liang D., Li J.Y., Zhao R.Y. APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication. Retrovirology 2008, 5:72.
36. Ao Z., Wang X., Bello A., Jayappa K.D., Yu Z., Fowke K., He X., Chen X., Li J., Kobinger G., et al. Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages. Hum Gene Ther 2011, 22:1225-1237.
37. Anderson J., Akkina R. Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum Gene Ther 2008, 19:217-228.
38. Neagu M.R., Ziegler P., Pertel T., Strambio-De-Castillia C., Grutter C., Martinetti G., Mazzucchelli L., Grutter M., Manz M.G., Luban J. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest 2009, 119:3035-3047.
39. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
40. Wong-Staal F., Poeschla E.M., Looney D.J. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998, 9:2407-2425.
41. Cooper D., Penny R., Symonds G., Carr A., Gerlach W., Sun L.Q., Ely J. A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther 1999, 10:1401-1421.
42. Feng Y., Leavitt M., Tritz R., Duarte E., Kang D., Mamounas M., Gilles P., Wong-Staal F., Kennedy S., Merson J., et al. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 2000, 276:271-278.
43. Macpherson J.L., Boyd M.P., Arndt A.J., Todd A.V., Fanning G.C., Ely J.A., Elliott F., Knop A., Raponi M., Murray J., et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med 2005, 7:552-564.
44. Amado R.G., Mitsuyasu R.T., Rosenblatt J.D., Ngok F.K., Bakker A., Cole S., Chorn N., Lin L.S., Bristol G., Boyd M.P., et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 2004, 15:251-262.
45. Mitsuyasu R.T., Merigan T.C., Carr A., Zack J.A., Winters M.A., Workman C., Bloch M., Lalezari J., Becker S., Thornton L., et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009, 15:285-292.
46. Faghihi M.A., Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol 2009, 10:637-643.
47. Levine B.L., Humeau L.M., Boyer J., MacGregor R.R., Rebello T., Lu X., Binder G.K., Slepushkin V., Lemiale F., Mascola J.R., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006, 103:17372-17377.
48. Metzger V.T., Lloyd-Smith J.O., Weinberger L.S. Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput Biol 2011, 7:e1002015.
49. Weinberger L.S., Schaffer D.V., Arkin A.P. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol 2003, 77:10028-10036.
50. Kohn D.B., Bauer G., Rice C.R., Rothschild J.C., Carbonaro D.A., Valdez P., Hao Q., Zhou C., Bahner I., Kearns K., et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999, 94:368-371.
51. DiGiusto D.L., Krishnan A., Li L., Li H., Li S., Rao A., Mi S., Yam P., Stinson S., Kalos M., et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010, 2. 36ra43.
52. Das A.T., Brummelkamp T.R., Westerhout E.M., Vink M., Madiredjo M., Bernards R., Berkhout B. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004, 78:2601-2605.
53. Sabariegos R., Gimenez-Barcons M., Tapia N., Clotet B., Martinez M.A. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol 2006, 80:571-577.
54. Shah P.S., Pham N.P., Schaffer D.V. HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther 2012, 20:840-848.
55. Leonard J.N., Shah P.S., Burnett J.C., Schaffer D.V. HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe 2008, 4:484-494.
56. Saayman S., Arbuthnot P., Weinberg M.S. Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res 2010, 38:6652-6663.
57. ter Brake O., t Hooft K., Liu Y.P., Centlivre M., von Eije K.J., Berkhout B. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 2008, 16:557-564.
58. Zhang J., Rossi J.J. Strategies in designing multigene expression units to downregulate HIV-1. Methods Mol. Biol 2010, 623:123-136.
59. Schopman N.C., ter Brake O., Berkhout B. Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology 2010, 7:52.
60. Chung J., Zhang J., Li H., Ouellet D., Digiusto D.L., Rossi J.J. Endogenous MCM7 miRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy. Hum Gene Ther 2012, [Epub ahead of print].
61. Anderson J.S., Javien J., Nolta J.A., Bauer G. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther 2009, 17:2103-2114.
62. Walker J.E., Chen R.X., McGee J., Nacey C., Pollard R.B., Abedi M., Bauer G., Nolta J.A., Anderson J.S. Generation of an HIV-1-resistant immune system with CD34+ hematopoietic stem cells transduced with a triple-combination Anti-HIV lentiviral vector. J Virol 2012, 86:5719-5729.
63. Kiem H.P., Wu R.A., Sun G., von Laer D., Rossi J.J., Trobridge G.D. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther 2010, 17:37-49.
64. Burnett J.C., Rossi J.J., Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011, 6:1130-1146.
65. Abdel-Azim H., Zhu Y., Hollis R., Wang X., Ge S., Hao Q.L., Smbatyan G., Kohn D.B., Rosol M., Crooks G.M. Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood 2008, 111:4064-4074.
66. Okazuka K., Beard B.C., Emery D.W., Schwarzwaelder K., Spector M.R., Sale G.E., von Kalle C., Torok-Storb B., Kiem H.P., Blau C.A. Long-term regulation of genetically modified primary hematopoietic cells in dogs. Mol Ther 2011, 19:1287-1294.
67. Rossi J.J. Ribozyme therapy for HIV infection. Adv Drug Deliv Rev 2000, 44:71-78.
68. Liu D., Donegan J., Nuovo G., Mitra D., Laurence J. Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol 1997, 71:4079-4085.